Oral decitabine/cedazuridine

DRUG2 trials

Sponsors

Otsuka Australia Pharmaceutical Pty Ltd, Rutgers, The State University of New Jersey

Conditions

Acute Myeloid LeukemiaLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, ChronicMyelodysplastic SyndromesPatient Preference

Phase 1

Hydrochloroquinine & Decitabine With Venetoclax in AML

Not yet recruitingNCT07814339

Rutgers, The State University of New JerseyAcute Myeloid Leukemia

Start: 2026-09-01End: 2028-06-01Target: 18Updated: 2026-09-10

Phase 3

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

Active, not recruitingNCT05883956

Otsuka Australia Pharmaceutical Pty LtdLeukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic Syndromes +1

Start: 2023-12-20End: 2025-05-31Updated: 2025-03-20

Related Papers

PHASE 3B STUDY DESIGN: COMPARING TREATMENT PREFERENCE BETWEEN ORAL DECITABINE/CEDAZURIDINE AND AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME, LOW-BLAST ACUTE MYELOID LEUKAEMIA, OR CHRONIC MYELOMONOCYTIC LEUKAEMIA

Leukemia Research Reports2024-01-01

Phase 3b Study Design for a Comparison of Treatment Preference between Oral Decitabine/Cedazuridine and Azacitidine in Adult Patients with IPSS-R Intermediate Myelodysplastic Syndrome, IPSS Intermediate-2 or High-Risk Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukaemia, or Chronic Myelomonocytic Leukaemia

Blood2023-11-02